A detailed history of Ameritas Investment Partners, Inc. transactions in Denali Therapeutics Inc. stock. As of the latest transaction made, Ameritas Investment Partners, Inc. holds 12,592 shares of DNLI stock, worth $270,602. This represents 0.01% of its overall portfolio holdings.

Number of Shares
12,592
Previous 12,230 2.96%
Holding current value
$270,602
Previous $283,000 29.33%
% of portfolio
0.01%
Previous 0.01%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$20.96 - $31.05 $7,587 - $11,240
362 Added 2.96%
12,592 $366,000
Q4 2023

Feb 14, 2024

BUY
$16.2 - $23.18 $7,970 - $11,404
492 Added 4.19%
12,230 $262,000
Q3 2023

Nov 13, 2023

BUY
$20.63 - $30.17 $40,888 - $59,796
1,982 Added 20.32%
11,738 $242,000
Q2 2023

Aug 11, 2023

BUY
$23.37 - $32.96 $24,468 - $34,509
1,047 Added 12.02%
9,756 $287,000
Q4 2022

Feb 13, 2023

BUY
$26.28 - $33.92 $32,587 - $42,060
1,240 Added 16.6%
8,709 $242,000
Q2 2022

Aug 12, 2022

BUY
$20.88 - $35.19 $6,994 - $11,788
335 Added 4.7%
7,469 $219,000
Q2 2021

Aug 06, 2021

BUY
$50.3 - $78.44 $101,555 - $158,370
2,019 Added 39.47%
7,134 $560,000
Q1 2021

May 14, 2021

SELL
$53.8 - $81.53 $8,231 - $12,474
-153 Reduced 2.9%
5,115 $292,000
Q4 2020

Feb 12, 2021

SELL
$36.89 - $93.56 $10,587 - $26,851
-287 Reduced 5.17%
5,268 $441,000
Q2 2020

Aug 05, 2020

BUY
$16.01 - $28.82 $21,805 - $39,252
1,362 Added 32.48%
5,555 $134,000
Q4 2019

Feb 13, 2020

BUY
$14.4 - $19.99 $7,027 - $9,755
488 Added 13.17%
4,193 $73,000
Q3 2018

Nov 13, 2018

BUY
$12.46 - $21.74 $29,193 - $50,936
2,343 Added 172.03%
3,705 $81,000
Q1 2018

May 15, 2018

BUY
$15.36 - $24.8 $20,920 - $33,777
1,362 New
1,362 $27,000

Others Institutions Holding DNLI

About Denali Therapeutics Inc.


  • Ticker DNLI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 134,174,000
  • Market Cap $2.88B
  • Description
  • Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...
More about DNLI
Track This Portfolio

Track Ameritas Investment Partners, Inc. Portfolio

Follow Ameritas Investment Partners, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ameritas Investment Partners, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Ameritas Investment Partners, Inc. with notifications on news.